Biology:Mothers against decapentaplegic homolog 3

From HandWiki
Short description: Protein-coding gene in humans


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

Mothers against decapentaplegic homolog 3 also known as SMAD family member 3 or SMAD3 is a protein that in humans is encoded by the SMAD3 gene.[1][2]

SMAD3 is a member of the SMAD family of proteins. It acts as a mediator of the signals initiated by the transforming growth factor beta (TGF-β) superfamily of cytokines, which regulate cell proliferation, differentiation and death.[3][4] Based on its essential role in TGF beta signaling pathway, SMAD3 has been related with tumor growth in cancer development.

Gene

The human SMAD3 gene is located on chromosome 15 on the cytogenic band at 15q22.33. The gene is composed of 9 exons over 129,339 base pairs.[5] It is one of several human homologues of a gene that was originally discovered in the fruit fly Drosophila melanogaster.

The expression of SMAD3 has been related to the mitogen-activated protein kinase (MAPK/ERK pathway), particularly to the activity of mitogen-activated protein kinase kinase-1 (MEK1).[6] Studies have demonstrated that inhibition of MEK1 activity also inhibits SMAD3 expression in epithelial cells and smooth muscle cells, two cell types highly responsive to TGF-β1.[6]

Protein

SMAD3 is a polypeptide with a molecular weight of 48,080 Da. It belongs to the SMAD family of proteins. SMAD3 is recruited by SARA (SMAD Anchor for Receptor Activation) to the membrane, where the TGF-β receptor is located. The receptors for TGF-β, (including nodal, activin, myostatin and other family members) are membrane serine/threonine kinases that preferentially phosphorylate and activate SMAD2 and SMAD3.

Once SMAD3 is phosphorylated at the C-terminus, it dissociates from SARA and forms a heterodimeric complex with SMAD4, which is required for the transcriptional regulation of many target genes.[7] The complex of two SMAD3 (or of two SMAD2) and one SMAD4 binds directly to DNA though interactions of the MH1 domain. These complexes are recruited to sites throughout the genome by cell lineage-defining transcription factors (LDTFs) that determine the context-dependent nature of TGF-β action. The DNA binding sites in promoters and enhancers are known as the SMAD-binding elements (SBEs). These sites contain the CAG(AC)|(CC) and GGC(GC)|(CG) consensus sequences, the latter also known as 5GC sites.[8] The 5GC-motifs are highly represented as clusters of sites, in SMAD-bound regions genome-wide. These clusters can also contain CAG(AC)|(CC) sites. SMAD3/SMAD4 complex also binds to the TPA-responsive gene promoter elements, which have the sequence motif TGAGTCAG.[9]

Transcriptional coregulators, such as WWTR1 (TAZ), interact with SMAD3 to promote their function.

Structure

MH1 domain

The X-ray structures of the SMAD3 MH1 domain bound to the GTCT DNA reveal characteristic features of the fold. The MH1 structure consists of four-helices and three sets of antiparallel β-hairpins, one of which is used to interact with DNA. It also revealed the presence of a bound Zn2+, coordinated by His126, Cys64, Cys109 and Cys121 residues.[7][8] The main DNA binding region of the MH1 domain comprises the loop following the β1 strand, and the β2-β3 hairpin. In the complex with a member of the 5GC DNAs, the GGCGC motif, the convex face of the DNA-binding hairpin dives into the concave major groove of the duplex DNA containing five base pairs (GGCGC /'GCGCC'). In addition, the three residues strictly conserved in all R-SMADS and in SMAD4 (Arg74 and Gln76 located in β2 and Lys81 in β3 in SMAD3) participate in a network of specific hydrogen bonds with the dsDNA. Several tightly bound water molecules at the protein-DNA interface that contribute to the stabilization of the interactions have also been detected. The SMAD3 complex with the GGCGC site reveals that the protein-DNA interface is highly complementary and that one MH1 protein covers a DNA binding site of six base pairs.

MH2 domain

The MH2 domain mediates the interaction of R-SMADS with activated TGF-β receptors, and with SMAD4 after receptor-mediated phosphorylation of the Ser-X-Ser motif present in R-SMADS. The MH2 domain is also a binding platform for cytoplasmic anchors, DNA-binding cofactors, histone modifiers, chromatin readers, and nucleosome- positioning factors. The structure of the complex of SMAD3 and SMAD4 MH2 domains has been determined.[10] The MH2 fold is defined by two sets of antiparallel β-strands (six and five strands respectively) arranged as a β-sandwich flanked by a triple-helical bundle on one side and by a set of large loops and a helix on the other.

Functions and interactions

TGF-β/SMAD signaling pathway

SMAD3 functions as a transcriptional modulator, binding the TRE (TPA responsive element) in the promoter region of many genes that are regulated by TGF-β. SMAD3 and SMAD4 can also form a complex with c-Fos and c-jun at the AP-1/SMAD site to regulate TGF-β-inducible transcription.[9] The genes regulated by SMAD3-mediated TGFβ signaling affect differentiation, growth and death. TGF-β/SMAD signaling pathway has been shown to have a critical role in the expression of genes controlling differentiation of embryonic stem cells.[11] Some of the developmental genes regulated by this pathway include FGF1, NGF, and WNT11 as well as stem/progenitor cell associated genes CD34 and CXCR4.[12] The activity of this pathway as a regulator of pluripotent cell states requires the TRIM33-SMAD2/3 chromatin reading complex.[11]

TGF-β/SMAD3-induced repression

Besides the activity of TGF-β in the up-regulation of genes, this signaling molecule also induces the repression of target genes containing the TGF-β inhibitory element (TIE).[13][14] SMAD3 plays also a critical role in TGF-β-induced repression of target genes, specifically it is required for the repression of c-myc. The transcriptional repression of c-myc is dependent on direct SMAD3 binding to a repressive SMAD binding element (RSBE), within TIE of the c-myc promoter. The c-myc TIE is a composite element, composed of an overlapping RSBE and a consensus E2F site, which is capable of binding at least SMAD3, SMAD4, E2F4, and p107.[14]

Clinical significance

Diseases

Increased SMAD3 activity has, however, been implicated in the pathogenesis of scleroderma.

SMAD3 is also a multifaceted regulator in adipose physiology and the pathogenesis of obesity and type 2 diabetes. SMAD3-knockout mice have diminished adiposity,[15] with improved glucose tolerance and insulin sensitivity. Despite their reduced physical activity arising from muscle atrophy,[16] these SMAD3-knockout mice are resistant to high-fat-diet induced obesity. SMAD3-knockout mouse is a legitimate animal model of human aneurysms‐osteoarthritis syndrome (AOS), also named Loeys-Dietz Syndrome (type 3). SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via the activation of iNOS. Macrophage depletion and inhibition of iNOS activity prevent aortic aneurysms related to SMAD3 gene mutation[17]

Role in cancer

The role of SMAD3 in the regulation of genes important for cell fate, such as differentiation, growth and death, implies that an alteration in its activity or repressing of its activity can lead to the formation or development of cancer. Also several studies have proven the bifunctional tumor suppressor/oncogene role of TGF beta signaling pathway in carcinogenesis.[18]

One way in which SMAD3 transcriptional activator function is repressed, is by the activity of EVI-1.[19] EVI-1 encodes a zinc-finger protein that may be involved in leukaemic transformation of haematopoietic cells. The zinc-finger domain of EVI-1 interacts with SMAD3, thereby suppressing the transcriptional activity of SMAD3. EVI-1 is thought to be able to promote growth and to block differentiation in some cell types by repressing TGF-β signalling and antagonizing the growth-inhibitory effects of TGF-β.[19]

Prostate

The activity of SMAD3 in prostate cancer is related with the regulation of angiogenic molecules expression in tumor vascularization and cell-cycle inhibitor in tumor growth.[20][21] The progressive growth of primary tumors and metastases in prostate cancer depends on an adequate blood supply provided by tumor angiogenesis. Studies analyzing SMAD3 levels of expression in prostate cancer cell lines found that the two androgen-independent and androgen receptor-negative cell lines (PC-3MM2 and DU145) have high expression levels of SMAD3. Analysis of the relation between SMAD3 and the regulation of angiogenic molecules suggest that SMAD3 may be one of key components as a repressor of the critical angiogenesis switch in prostate cancer.[21] The pituitary tumor-transforming gene 1 (PTTG1) has also an impact in SMAD3-mediated TGFβ signaling. PTTG1 has been associated with various cancer cells including prostate cancer cells. Studies showed that the overexpression of PTTG1 induces a decrease in SMAD3 expression, promoting the proliferation of prostate cancer cells via the inhibition of SMAD3.[20]

Colorectal

In mice, mutation of SMAD3 has been linked to colorectal adenocarcinoma,[3] increased systemic inflammation, and accelerated wound healing.[4] Studies have shown that mutations in SMAD3 gene promote colorectal cancer in mice.[22][23][24] The altered activity of SMAD3 was linked to chronic inflammation and somatic mutations that contribute to chronic colitis and the development of colorectal cancer.[24] The results generated on mice helped identify SMAD3 like a possible player in human colorectal cancer. The impact of SMAD3 has also been analyzed in colorectal cancer human cell lines, using single-nucleotide polymorphism (SNP) microarray analysis. The results showed reductions in SMAD3 transcriptional activity and SMAD2-SMAD4 complex formation, underlining the critical roles of these three proteins within the TGF-β signaling pathway and the impact of this pathway in colorectal cancer development.[25]

Breast

TGF-β-induced SMAD3 transcriptional regulation response has been associated with breast cancer bone metastasis by its effects on tumor angiogenesis, and epithelial-mesenchymal transition (EMT). There have been identified diverse molecules that act over the TGF-β/SMAD signaling pathway, affecting primarily the SMAD2/3 complex, which have been associated with the development of breast cancer.[26]

FOXM1 (forkhead box M1) is a molecule that binds with SMAD3 to sustain activation of the SMAD3/SMAD4 complex in the nucleus. The research over FOXM1 suggested that it prevents the E3 ubiquitin-protein ligase transcriptional intermediary factor 1 γ (TIF1γ) from binding SMAD3 and monoubiquitinating SMAD4, which stabilized the SMAD3/SMAD4 complex. FOXM1 is a key player in the activity of the SMAD3/SMAD4 complex, promoting SMAD3 modulator transcriptional activity, and also plays an important role in the turnover of the activity of SMAD3/SMAD4 complex. Based on the importance of this molecule, studies have found that FOXM1 is overexpressed in highly aggressive human breast cancer tissues. The results from these studies also found that the FOXM1/SMAD3 interaction was required for TGF-β-induced breast cancer invasion, which was the result of SMAD3/SMAD4-dependent upregulation of the transcription factor SLUG.[27]

MED15 is a mediator molecule that promotes the activity of the TGF-β/SMAD signaling. The deficiency of this molecule attenuates the activity of the TGF-β/SMAD signaling pathway over the genes required for induction of epithelial-mesenchymal transition. The action of MED15 is related with the phosphorylation of SMAD2/3 complex. The knockdown of MED15 reduces the amount of SMAD3 phosphorylated, therefore reducing its activity as transcription modulator. However, in cancer, MED15 is also highly expressed in clinical breast cancer tissues correlated with hyperactive TGF-β signaling, as indicated by SMAD3 phosphorylation. The studies suggest that MED15 increases the metastatic potential of a breast cancer cell line by increasing TGF-β-induced epithelial–mesenchymal transition.[28]

Kidney

Smad3 activation plays a role in the pathogenesis of renal fibrosis,[29] probably by inducing activation of bone marrow-derived fibroblasts.[30]

Nomenclature

The SMAD proteins are homologs of both the Drosophila protein "mothers against decapentaplegic" (MAD) and the C. elegans protein SMA. The name is a combination of the two. During Drosophila research, it was found that a mutation in the gene MAD in the mother repressed the gene decapentaplegic in the embryo. The phrase "Mothers against" was inspired by organizations formed by mothers to oppose social problems, such as Mothers Against Drunk Driving (MADD); and based on a tradition of such unusual naming within the gene research community.[31]

A reference assembly of SMAD3 is available.

References

  1. ↑ "Entrez Gene: SMAD3 SMAD family member 3". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4088. 
  2. ↑ "Receptor-associated Mad homologues synergize as effectors of the TGF-beta response". Nature 383 (6596): 168–172. September 1996. doi:10.1038/383168a0. PMID 8774881. Bibcode: 1996Natur.383..168Z. 
  3. ↑ "TGF-beta signal transduction". Annual Review of Biochemistry 67 (1): 753–791. 1998. doi:10.1146/annurev.biochem.67.1.753. PMID 9759503. 
  4. ↑ "Smad regulation in TGF-beta signal transduction". Journal of Cell Science 114 (Pt 24): 4359–4369. December 2001. doi:10.1242/jcs.114.24.4359. PMID 11792802. 
  5. ↑ GeneCards. "SMAD3 Gene". https://www.genecards.org/cgi-bin/carddisp.pl?gene=SMAD3&search=smad3. 
  6. ↑ 6.0 6.1 "SMAD3 expression is regulated by mitogen-activated protein kinase kinase-1 in epithelial and smooth muscle cells". Cellular Signalling 19 (5): 923–931. May 2007. doi:10.1016/j.cellsig.2006.11.008. PMID 17197157. 
  7. ↑ 7.0 7.1 "Mechanisms of TGF-beta signaling from cell membrane to the nucleus". Cell 113 (6): 685–700. June 2003. doi:10.1016/S0092-8674(03)00432-X. PMID 12809600. 
  8. ↑ 8.0 8.1 "Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors". Nature Communications 8 (1): 2070. December 2017. doi:10.1038/s41467-017-02054-6. PMID 29234012. Bibcode: 2017NatCo...8.2070M. 
  9. ↑ 9.0 9.1 "Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription". Nature 394 (6696): 909–913. August 1998. doi:10.1038/29814. PMID 9732876. Bibcode: 1998Natur.394..909Z. 
  10. ↑ "Structural basis of heteromeric smad protein assembly in TGF-beta signaling". Molecular Cell 15 (5): 813–823. September 2004. doi:10.1016/j.molcel.2004.07.016. PMID 15350224. 
  11. ↑ 11.0 11.1 "TGF-β control of stem cell differentiation genes". FEBS Letters 586 (14): 1953–1958. July 2012. doi:10.1016/j.febslet.2012.03.023. PMID 22710171. 
  12. ↑ "TGF-β/Smad3 stimulates stem cell/developmental gene expression and vascular smooth muscle cell de-differentiation". PLOS ONE 9 (4): e93995. 2014. doi:10.1371/journal.pone.0093995. PMID 24718260. Bibcode: 2014PLoSO...993995S. 
  13. ↑ "Negative regulation of gene expression by TGF-beta". Molecular Reproduction and Development 32 (2): 111–120. June 1992. doi:10.1002/mrd.1080320206. PMID 1637549. 
  14. ↑ 14.0 14.1 "Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element". Molecular and Cellular Biology 24 (6): 2546–2559. March 2004. doi:10.1128/mcb.24.6.2546-2559.2004. PMID 14993291. 
  15. ↑ "Smad3 deficiency in mice protects against insulin resistance and obesity induced by a high-fat diet". Diabetes 60 (2): 464–476. February 2011. doi:10.2337/db10-0801. PMID 21270259. 
  16. ↑ "Smad3 signaling is required for satellite cell function and myogenic differentiation of myoblasts". Cell Research 21 (11): 1591–1604. November 2011. doi:10.1038/cr.2011.72. PMID 21502976. 
  17. ↑ "SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS". Journal of the American Heart Association 2 (3): e000269. June 2013. doi:10.1161/JAHA.113.000269. PMID 23782924. 
  18. ↑ "Role of transforming growth factor-beta signaling in cancer". Journal of the National Cancer Institute 92 (17): 1388–1402. September 2000. doi:10.1093/jnci/92.17.1388. PMID 10974075. 
  19. ↑ 19.0 19.1 "The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3". Nature 394 (6688): 92–96. July 1998. doi:10.1038/27945. PMID 9665135. Bibcode: 1998Natur.394...92K. 
  20. ↑ 20.0 20.1 "PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation". Tumour Biology 35 (7): 6265–6270. July 2014. doi:10.1007/s13277-014-1818-z. PMID 24627133. 
  21. ↑ 21.0 21.1 "Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice". Clinical Cancer Research 13 (19): 5692–5702. October 2007. doi:10.1158/1078-0432.CCR-07-1078. PMID 17908958. 
  22. ↑ "Involvement of Smad3 phosphoisoform-mediated signaling in the development of colonic cancer in IL-10-deficient mice". International Journal of Oncology 32 (6): 1221–1226. June 2008. doi:10.3892/ijo.32.6.1221. PMID 18497983. 
  23. ↑ "Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in Smad3(-/-) mice with dysregulated TGFβ". PLOS ONE 8 (11): e79182. 2013. doi:10.1371/journal.pone.0079182. PMID 24244446. Bibcode: 2013PLoSO...879182S. 
  24. ↑ 24.0 24.1 "Oncogenic Smad3 signaling induced by chronic inflammation is an early event in ulcerative colitis-associated carcinogenesis". Inflammatory Bowel Diseases 17 (3): 683–695. March 2011. doi:10.1002/ibd.21395. PMID 20602465. 
  25. ↑ "SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer". Cancer Research 73 (2): 725–735. January 2013. doi:10.1158/0008-5472.CAN-12-2706. PMID 23139211. 
  26. ↑ "Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis". Oncogene 29 (9): 1351–1361. March 2010. doi:10.1038/onc.2009.426. PMID 20010874. 
  27. ↑ "Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis". The Journal of Clinical Investigation 124 (2): 564–579. February 2014. doi:10.1172/JCI71104. PMID 24382352. 
  28. ↑ "Mediator MED15 modulates transforming growth factor beta (TGFβ)/Smad signaling and breast cancer cell metastasis". Journal of Molecular Cell Biology 5 (1): 57–60. February 2013. doi:10.1093/jmcb/mjs054. PMID 23014762. 
  29. ↑ "Role of the TGF-β/BMP-7/Smad pathways in renal diseases". Clinical Science 124 (4): 243–254. February 2013. doi:10.1042/CS20120252. PMID 23126427. 
  30. ↑ "Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis". Laboratory Investigation; A Journal of Technical Methods and Pathology 94 (5): 545–556. May 2014. doi:10.1038/labinvest.2014.43. PMID 24614197. 
  31. ↑ White, Michael. "The Problem With Naming Genes" (in en). https://psmag.com/environment/sonic-hedgehog-dicer-problem-naming-genes-91386. 

Further reading

External links

  • Overview of all the structural information available in the PDB for UniProt: P84022 (Mothers against decapentaplegic homolog 3) at the PDBe-KB.



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Mothers_against_decapentaplegic_homolog_3&oldid=3653173"